From June 16-19, 2025, the 2025 Biotechnology Innovation Organization International Convention (“BIO 2025”) will be held in Boston, Massachusetts, USA. For conference attendees, Henlius will showcase its six commercialized products and a robust pipeline of 20+ investigational therapies at Booth #1885.
BIO International Convention, produced by BIO (Biotechnology Innovation Organization), is the world’s largest and most influential gathering of the biotechnology industry along with industry-leading companies, investors, and partnering meetings held around the world. The 2025 edition in Boston is anticipated to convene over 15,000 industry professionals to explore cutting-edge innovations and strategic collaborations in biopharma.
During BIO 2025, the company will be at Booth #1885 with 6 launched products, including HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe)，HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANLIKANG (rituximab), the first China-developed biosimilar, HANBEITAI (bevacizumab), HANDAYUAN (adalimumab), and HANNAIJIA (neratinib). Apart from serplulimab, the company's portfolio of innovative products under investigation will also be showcased, featuring HLX22, an anti-HER2 monoclonal antibody with FDA ODD, HLX43, the world's second PD-L1-targeting ADC candidate in clinical development. Simultaneously, Henlius will also present its innovative R&D platforms, including the Hinova TCE (tri-specific T-cell engager) platform, the independently developed ADC platform Hanjugator™, the AI-driven drug discovery platform HAI Club, and Henozye™, a next-generation hyaluronidase powered by AI technology.
Henlius is determined to offer high-quality, affordable, and innovative biologic medicines for patients worldwide, pioneering breakthrough innovations with a strategic focus on oncology. We continue to expand global partnerships and warmly invite you to visit booth #1885 at the Boston Convention & Exhibition Center.